Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: CCA, ERP, FVT

Select Medical Holdings Corporation Announces Estimate of Certain Financial Results for its Year Ended December 31, 2021 and Date of Issuance of Actual Financial Results


MECHANICSBURG, Pa., Jan. 17, 2022 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced an estimate of certain results for its full year ended December 31, 2021 in advance of the announcement of actual results. Select Medical will release its actual financial results for its fourth quarter and full year ended December 31, 2021 on Thursday, February 24, 2022 after the market closes.

Select Medical expects its net operating revenue for the year ended December 31, 2021 to be approximately $6,204 million. Select Medical expects earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries, or Adjusted EBITDA, for the year ended December 31, 2021 to be approximately $947 million. Select Medical expects fully diluted earnings per common share for the year ended December 31, 2021 to be in the range of $2.90 to $2.92. When Select Medical issues its business outlook for the year ended December 31, 2022, it will readdress its target compound annual growth rates for revenue, Adjusted EBITDA, and earnings per common share.

The above expectations regarding Select Medical's results for the year ended December 31, 2021 are management estimates and projections based on currently available information, and are subject to change upon completion of Select Medical's financial statement closing process and audit.

A reconciliation of full year 2021 Adjusted EBITDA expectations to the closest comparable GAAP financial measure is presented in table I of this release. Please refer to Select Medical's most recent Form 10-Q filing for a discussion of Select Medical's use of Adjusted EBITDA in evaluating financial performance and determining resource allocation. Each item presented in table I is an estimation of full year 2021 expectations (dollars in millions).

Our business outlook issued on November 4, 2021 reflected the best information available at the time and our best estimates about the financial forecast of Select Medical for the year ending December 31, 2021. During the fourth quarter however, we experienced, predominantly in our critical illness recovery hospital segment, a higher than expected use of agency clinical staff and higher than expected costs for agency in our hospitals. This unexpected significant increase in our labor costs had a detrimental effect on our Adjusted EBITDA and diluted earnings per common share for the quarter and year ended December 31, 2021.

The unpredictable effects of the COVID-19 pandemic, including the duration and extent of disruption on Select Medical's operations and increases to our labor costs, creates uncertainties about Select Medical's future operating results and financial condition. Please refer to our risk factors previously reported in our Annual Report on Form 10-K for the year ended December 31, 2020 and our Quarterly Reports on Form 10-Q for further discussion.

Select Medical will host a conference call regarding its fourth quarter and full year results, as well as its business outlook, on Friday, February 25, 2022, at 9:00am ET. The domestic dial in number for the call is 1-866-440-2669. The international dial in number is 1-409-220-9844. The conference ID for the call is 7334656. The conference call will be webcast simultaneously and can be accessed at Select Medical Holdings Corporation's website at www.selectmedicalholdings.com.

For those unable to participate in the conference call, a replay will be available until 12:00pm ET, March 4, 2022. The replay number is 1-855-859-2056 (domestic) or 1-404-537-3406 (international). The conference ID for the replay will be 7334656. The replay can also be accessed at Select Medical Holdings Corporation's website at www.selectmedicalholdings.com.

Company Overview

Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States based on number of facilities. Select Medical's reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. As of December 31, 2021, Select Medical operated 104 critical illness recovery hospitals in 28 states, 30 rehabilitation hospitals in 12 states, and 1,881 outpatient rehabilitation clinics in 38 states and the District of Columbia. Concentra operated 518 occupational health centers in 41 states. At December 31, 2021, Select Medical had operations in 46 states and the District of Columbia. Information about Select Medical is available at www.selectmedicalholdings.com.

Certain statements contained herein that are not descriptions of historical facts are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Select Medical's 2021 results and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investor inquiries:

Joel T. Veit
Senior Vice President and Treasurer
717-972-1100
[email protected]

 

I. Net Income to Adjusted EBITDA Reconciliation


Business Outlook for the Year Ending December 31, 2021


(In millions, unaudited)




Non-GAAP Measure Reconciliation(1)


Net income attributable to Select Medical

$                    394

Net income attributable to non-controlling interests

98

Net income

492

Income tax expense(2)

137

Interest income

(5)

Interest expense

136

Gain on sale of businesses

(2)

Equity in earnings of unconsolidated subsidiaries

(44)

Income from operations

714

Stock compensation expense

31

Depreciation and amortization

202

Adjusted EBITDA

$                    947






(1)

These amounts are subject to change upon completion of Select Medical's financial statement closing process and audit.

(2)

Income tax expense is estimated to be between $137.0 million and $141.0 million.

 

SOURCE Select Medical Holdings Corporation


These press releases may also interest you

at 20:09
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead...

at 19:30
Results  For the year ended January 31, 2024, the Company's revenues decreased by $139,027,000 to $578,945,000 compared to $717,972,000 recorded for the year ended January 31, 2023, a decrease of 19.4%. This decrease is mainly explained by the...

at 19:30
Lendistry announces today that it has been selected to administer the Entertainment Business Interruption Fund Program (BIF) to support small Los Angeles County businesses serving the entertainment industry. This program, created and funded through...

at 18:40
Rocky Mountain Liquor Inc. (the "Company" or "Rocky Mountain"), listed on the TSX Venture Exchange (the "Exchange"), today reported its financial results for the full year and fourth quarter ended December 31, 2023.KEY...

at 18:05
Guanajuato Silver Company Ltd. (the "Company" or "GSilver") announces a brokered, best-efforts Listed Issuer Financing Exemption private placement (the "Offering") consisting of units of the Company (the "Units") at a price of C$0.20 per Unit (the...

at 17:25
Customers Bancorp, Inc. : First Quarter 2024 Highlights Q1 2024 net income available to common shareholders was $45.9 million, or $1.40 per diluted share; ROAA was 0.94% and ROCE was 12.08%. Q1 2024 core earnings* were $46.5 million, or $1.42...



News published on and distributed by: